Results 131 to 140 of about 1,030,601 (304)

Current Validated Clinical and Patient Reported Disease Outcome Measures in Juvenile Idiopathic Arthritis

Open Access Rheumatology: Research and Reviews, 2023
Erin Balay-Dustrude,1,2 Susan Shenoi1,2 1Department of Pediatrics, Division of Rheumatology, University of Washington, Seattle, WA, USA; 2Department of Pediatric Rheumatology, Seattle Children’s Hospital and Research Center, Seattle, WA ...
Balay-Dustrude E, Shenoi S
doaj  

Etoposide‐induced cancer cell death: roles of mitochondrial VDAC1 and calpain, and resistance mechanisms

Molecular Oncology, EarlyView.
The complex mode of action of the topoisomerase II inhibitor etoposide in triggering apoptosis involves several mechanisms: overexpression of the mitochondrial protein VDAC1, leading to its oligomerization and formation of a large channel that mediates the release of pro‐apoptotic protein; and overexpression of the apoptosis regulators p53, Bax, and ...
Aditya Karunanithi Nivedita, Varda Shoshan‐Barmatz   +1 more
wiley   +1 more source

Educating patients about patient-reported outcomes—are we there yet?

Journal of Patient-Reported Outcomes
Background Using Patient Reported Outcome Measures (PROMs) in clinical settings can improve patient outcomes by enhancing communication between patient and provider.
Elizabeth Unni, Maud M. van Muilekom, Kate Absolom, Bishnu Bajgain, Lotte Haverman, Maria Santana   +5 more
doaj   +1 more source

Patient-reported outcome measures in orthopaedics

Danish Medical Journal
INTRODUCTION. The Patient Activity Treatment Outcome Scale (PATOS) is a novel patient-reported outcome measure (PROM). This study explored patients’ and orthopaedic surgeons’ experiences with PATOS as part of a PROM battery. It aimed to investigate its influence on patient involvement and healthcare decisions about knee or hip osteoarthritis patients ...
Hansen, Stine Thestrup, Jensen, Rasmus Stig, Holm, Henriette Appel, Liljensøe, Anette   +3 more
openaire   +2 more sources

An index of only patient-reported outcome measures, routine assessment of patient index data 3 (RAPID3), in two abatacept clinical trials: similar results to disease activity score (DAS28) and other RAPID indices that include physician-reported measures [PDF]

, 2007
Theodore Pincus, Martin Bergman, Yusuf Yazıcı, P. Hines, Kartik Raghupathi, Ross Maclean   +5 more
openalex   +1 more source

Respiratory complex I‐mediated NAD+ regeneration regulates cancer cell proliferation through the transcriptional and translational control of p21Cip1 expression by SIRT3 and SIRT7

Molecular Oncology, EarlyView.
NAD+ regeneration by mitochondrial complex I NADH dehydrogenase is important for cancer cell proliferation. Specifically, NAD+ is necessary for the activities of NAD+‐dependent deacetylases SIRT3 and SIRT7, which suppress the expression of p21Cip1 cyclin‐dependent kinase inhibitor, an antiproliferative molecule, at the translational and transcriptional
Masato Higurashi, Kazunori Mori, Hidetsugu Nakagawa, Momoko Uchida, Fumihiro Ishikawa, Motoko Shibanuma   +5 more
wiley   +1 more source

The Cervical Dystonia Impact Profile (CDIP-58): Can a Rasch developed patient reported outcome measure satisfy traditional psychometric criteria? [PDF]

, 2008
Stefan Cano, Thomas T. Warner, Alan J. Thompson, Kailash P. Bhatia, Ray Fitzpatrick, Jeremy Hobart   +5 more
openalex   +1 more source

Analysis of comprehensive genomic profiling of solid tumors with a novel assay for broad analysis in clinical diagnostics

Molecular Oncology, EarlyView.
In molecular cancer diagnostics, comprehensive genomic profiling (CGP) is going to replace the small NGS panels since it provides all clinically relevant somatic variants as well as genomic biomarkers with clinical value. Here, we compared two CGP assays and demonstrate that the choice for diagnostic implementation will depend on the specific ...
Guy Froyen, Pieter‐Jan Volders, Ellen Geerdens, Severine Berden, Joni Van der Meulen, Aaron De Cock, Stefanie Vermeire, Jacques Van Huysse, Marie de Barsy, Gabriela Beniuga, Wendy W. J. de Leng, Anne M. L. Jansen, Imke Demers, Zeliha Ozgur, Hendrikus Jan Dubbink, Ernst‐Jan M. Speel, Wilfred F. J. van IJcken, Brigitte Maes   +17 more
wiley   +1 more source

Response to neoadjuvant chemotherapy in early breast cancers is associated with epithelial–mesenchymal transition and tumor‐infiltrating lymphocytes

Molecular Oncology, EarlyView.
Epithelial–mesenchymal transition (EMT) and tumor‐infiltrating lymphocytes (TILs) are associated with early breast cancer response to neoadjuvant chemotherapy (NAC). This study evaluated EMT and TIL shifts, with immunofluorescence and RNA sequencing, at diagnosis and in residual tumors as potential biomarkers associated with treatment response.
Françoise Derouane, Jérôme Ambroise, Cédric van Marcke, Mieke Van Bockstal, Martine Berlière, Christine Galant, Hélène Dano, Médina Lougué, Elena Benidovskaya, Guy Jerusalem, Vincent Bours, Claire Josse, Jérôme Thiry, Aurélie Daumerie, Caroline Bouzin, Cyril Corbet, François P. Duhoux   +16 more
wiley   +1 more source

Measuring irritable bowel syndrome patient‐reported outcomes with an abdominal pain numeric rating scale [PDF]

, 2009
Brennan Spiegel, Roger Bolus, Lucinda A. Harris, Susan Lucak, Bruce D. Naliboff, Eric Esrailian, William D. Chey, Anthony Lembo, Hetal A. Karsan, Kirsten Tillisch, Jennifer Talley, Emeran A. Mayer, Lin Chang   +12 more
openalex   +1 more source